SEC
ends
Original fundamental research starts and ENDS here.
Sectors
Tags
Blog
Search
VRTX
30 filings
Timeline
Columns
Start Research
8-K Categories
2025
Q4
2 filings
Nov
Q3 2025 Results
Unable to extract revenue and EPS figures from provided XBRL data
10-Q
Nov
Q3 2025 Earnings
Financial results for three and nine months ended September 30, 2025
8-K
Q3
2 filings
Aug
Q2 2025 Results
Unable to extract specific revenue and EPS figures from provided XBRL metadata
10-Q
Aug
Q2 Earnings + CSO Retirement
David Altshuler CSO retiring Aug 2026
8-K
Q2
5 filings
May
Share Repurchase Program
$4B new buyback authorized, $4.775B total capacity
8-K
May
Annual Shareholder Meeting
11 directors elected, Ernst & Young ratified as auditor
8-K
May
Q1 2025 Results
Unable to extract revenue and EPS data from provided content
10-Q
May
Q1 2025 Earnings
Q1 2025 financial results reported May 5, 2025
8-K
Apr
2024 Proxy Statement
Annual meeting: May 14, 2025 (virtual), Record date: March 17, 2025
DEF 14A
Q1
3 filings
Mar
VX-264 Program Discontinued
$400M impairment charge for Q1 2025
8-K
Feb
FY24 2024 Results
Data insufficient - revenue and EPS figures not extractable from provided XBRL tags
📌 Data insufficient - specific operational milestones not extractable from provided XBRL metadata
10-K
Feb
Q4 Earnings + COO Change
Stuart Arbuckle COO retires July 1, CFO Wagner adds COO role
8-K
2024
Q4
3 filings
Dec
FDA Approves ALYFTREK
ALYFTREK approved for cystic fibrosis, priced at $370,269 annually
8-K
Nov
Q3 2024 Results
Financial data not available in provided XBRL extract
10-Q
Nov
Q3 Earnings
Q3 2024 financial results reported
8-K
Q3
3 filings
Aug
Headquarters Lease Extension
1.1M sq ft lease extended to June 2044
8-K
Aug
Q2 2024 Results
Unable to extract revenue and EPS figures from provided XBRL data structure
10-Q
Aug
Q2 Earnings
Q2 2024 financial results reported
8-K
Q2
7 filings
Jun
Alpine Acquisition Accounting Impact
$4.4B AIPR&D expense from $5B Alpine acquisition
8-K
May
Acquired Alpine Immune Sciences
$5.0B equity value deal completed
8-K
May
Annual Shareholder Meeting
11 directors elected, auditor ratified, exec comp approved
8-K
May
Q1 2024 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
10-Q
May
Q1 2024 Earnings
Q1 2024 financial results reported
8-K
Apr
Acquired Alpine Immune Sciences
$65/share cash tender offer
8-K
Apr
2024 Proxy Statement
CEO comp: Not disclosed, Say-on-pay: Advisory vote scheduled
DEF 14A
Q1
2 filings
Feb
FY 2023 Results
Unable to extract specific revenue and EPS figures from provided XBRL data
📌 Unable to identify specific milestone from provided XBRL data format
10-K
Feb
Q4 2023 Earnings
Q4 and full year 2023 financial results reported
8-K
2023
Q4
3 filings
Dec
FDA Approves CASGEVY
Gene therapy for sickle cell disease, $2.2M wholesale price
8-K
Dec
Nancy Thornberry Appointed to Board
Board expanded from 10 to 11 members, $400K RSU grant
8-K
Nov
Q3 2023 Results
Financial figures not available in provided excerpt
10-Q